从澳大利亚猫身上分离出的快速生长分枝杆菌对伊维菌素、莫西菌素、头孢噻呋和氟苯尼考的敏感性。
Susceptibility of rapidly growing mycobacteria isolated from Australian cats to ivermectin, moxidectin, ceftiofur and florfenicol.
作者信息
Woerde Dennis J, Martin Patricia A, Govendir Merran
机构信息
Faculty of Veterinary Science, The University of Sydney, Sydney, NSW, Australia.
Faculty of Veterinary Science, The University of Sydney, Sydney, NSW, Australia
出版信息
J Feline Med Surg. 2015 Dec;17(12):1065-8. doi: 10.1177/1098612X14565497. Epub 2015 Jan 8.
OBJECTIVES
Rapidly growing mycobacteria (RGM) infections in cats typically manifest as a panniculitis, requiring long-term antimicrobial therapy for resolution. The search for novel antimicrobial therapies to reduce treatment duration and improve the rate of clinical resolution is imperative. Accordingly, RGM isolates underwent susceptibility testing to some avermectins and other antibacterial drugs currently available.
METHODS
Five Mycobacterium fortuitum and six Mycobacterium smegmatis isolates obtained from Australian cats underwent susceptibility testing by microbroth dilution to ivermectin, moxidectin, ceftiofur and florfenicol.
RESULTS
All isolates were resistant to the highest concentrations of ivermectin, moxidectin and ceftiofur tested (1024 µg/ml, 256 μg/ml and 32 μg/ml, respectively). All isolates of M fortuitum were resistant to the highest concentration of florfenicol tested (128 µg/ml). The minimum inhibitory concentration range of florfenicol that inhibited growth of M smegmatis isolates was 32-64 µg/ml.
CONCLUSIONS AND RELEVANCE
All drugs appear to have no efficacy in vitro for the treatment of RGM infections.
目的
猫的快速生长分枝杆菌（RGM）感染通常表现为脂膜炎，需要长期抗菌治疗才能治愈。寻找新的抗菌疗法以缩短治疗时间并提高临床治愈率势在必行。因此，对RGM分离株进行了对目前可用的一些阿维菌素和其他抗菌药物的药敏试验。
方法
从澳大利亚猫中分离出的5株偶然分枝杆菌和6株耻垢分枝杆菌，通过微量肉汤稀释法对伊维菌素、莫西菌素、头孢噻呋和氟苯尼考进行药敏试验。
结果
所有分离株对所测试的伊维菌素、莫西菌素和头孢噻呋的最高浓度（分别为1024μg/ml、256μg/ml和32μg/ml）均耐药。所有偶然分枝杆菌分离株对所测试的氟苯尼考最高浓度（128μg/ml）均耐药。抑制耻垢分枝杆菌分离株生长的氟苯尼考最低抑菌浓度范围为32 - 64μg/ml。
结论及意义
所有药物在体外对RGM感染似乎均无疗效。
Zotero 插件